Table 2.
Demographic and disease characteristics of patient at Baseline
| Characteristics | Secukinumab 300 mg (n = 221) | Secukinumab 150 mg (n = 110) | Placebo (n = 110) | Total (n = 441) |
| Age (years) | 39.0 ± 11.6 | 40.5 ± 10.8 | 38.7 ± 10.3 | 39.3 ± 11.1 |
| Male | 177 (80.1) | 84 (76.4) | 89 (80.9) | 350 (79.4) |
| Bodyweight (kg) | 73.25 ± 14.24 | 72.71 ± 15.47 | 72.63 ± 13.27 | 72.96 ± 14.29 |
| PASI | ||||
| Total | 27.3 ± 10.9 | 26.5 ± 10.6 | 26.2 ± 9.3 | 26.8 ± 10.4 |
| >20 | 154 (69.7) | 76 (69.1) | 78 (70.9) | 308 (69.8) |
| BSA involvement | 46.5 ± 20.7 | 44.8 ± 19.9 | 44.0 ± 19.2 | 45.4 ± 20.1 |
| IGA mod 2011 score | ||||
| 3-Moderate disease | 117 (52.9) | 64 (58.2) | 63 (57.3) | 244 (55.3) |
| 4-Severe disease | 104 (47.1) | 46 (41.8) | 47 (42.7) | 197 (44.7) |
| Mean time since first diagnosis of plaque-type psoriasis (years) | 15.0 ± 9.2 | 16.2 ± 9.6 | 14.8 ± 9.2 | 15.3 ± 9.3 |
| Previous exposure to biologic psoriasis therapy | 33 (14.9) | 24 (21.8) | 23 (20.9) | 80 (18.1) |
| Psoriasis arthritis present∗ | 23 (10.4) | 11 (10.0) | 11 (10.0) | 45 (10.2) |
All data are expressed as mean ± standard deviation or n (%).
∗
Defined as at least three points out of the clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) criteria and at least three tender and three swollen joints at Baseline. PASI: Psoriasis Area and Severity Index; BSA: Body surface area; IGA mod 2011: Investigator's Global Assessment, 2011 modification.